| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
5-Amino-8-hydroxyquinoline targets the proteasome, a multi-subunit protease complex responsible for degrading ubiquitinated proteins. By inhibiting proteasome activity, the compound disrupts protein degradation pathways, leading to accumulation of ubiquitinated proteins and induction of apoptosis in cancer cells. The compound's ability to chelate metal ions may also contribute to its biological activity. The 8-hydroxyquinoline scaffold is known for diverse biological activities including anticancer, antimicrobial, and neuroprotective effects.
|
|---|---|
| ln Vitro |
In vitro, 5-Amino-8-hydroxyquinoline demonstrates notable proteasome inhibitory activity. The compound shows concentration-dependent inhibition of proteasome activity in biochemical assays using purified proteasome preparations. In cancer cell lines, 5-Amino-8-hydroxyquinoline induces apoptosis and inhibits cell proliferation. The compound's activity is attributed to its ability to bind to the proteasome active site or chelate metal ions required for proteasome function. Molecular weight is 160.17 and molecular formula is C₉H₈N₂O.
|
| ln Vivo |
In vivo activity data for 5-Amino-8-hydroxyquinoline are limited, as the compound is primarily studied in vitro. Based on its proteasome inhibitory mechanism and anticancer activity in cell-based models, the compound is expected to inhibit tumor growth in animal models. However, detailed efficacy studies in animal models have not been extensively reported. The compound's potential for in vivo applications requires further investigation, including pharmacokinetic and toxicological characterization.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for 5-Amino-8-hydroxyquinoline typically involves measuring the chymotrypsin-like, trypsin-like, or caspase-like activity of the 20S or 26S proteasome using fluorogenic peptide substrates. Purified proteasome is incubated with varying concentrations of the compound (0.1-100 µM) in assay buffer at 37°C for 30-60 minutes. The reaction is initiated by adding the substrate, and fluorescence is measured. Percent inhibition is calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, cancer cell lines such as HeLa, MCF-7, or HCT116 are cultured and treated with 5-Amino-8-hydroxyquinoline at concentrations ranging from 1-100 µM for 24-72 hours. Cell viability is assessed using MTT or CCK-8 assays. Proteasome activity is measured in cell lysates using fluorogenic substrates. Apoptosis is evaluated using Annexin V-FITC/PI double staining and caspase activity assays. Ubiquitinated protein accumulation is assessed by Western blot.
|
| Animal Protocol |
In vivo animal studies for 5-Amino-8-hydroxyquinoline have not been extensively reported. Based on the compound's mechanism as a proteasome inhibitor, potential in vivo studies would involve administration to tumor-bearing mouse models via oral gavage, intraperitoneal injection, or intravenous injection at doses ranging from 1-50 mg/kg. Tumor growth would be monitored by caliper measurements. Proteasome activity and apoptosis markers would be assessed in tumor tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 5-Amino-8-hydroxyquinoline have not been fully characterized. Molecular weight is 160.17 and molecular formula is C₉H₈N₂O. CAS number is 13207-66-4. The compound is soluble in various organic solvents. Detailed pharmacokinetic parameters such as bioavailability, half-life, and protein binding have not been reported. Stability in solution may be limited and fresh solutions should be prepared for each experiment.
|
| Toxicity/Toxicokinetics |
Toxicology data for 5-Amino-8-hydroxyquinoline are limited. As a research compound, it has not been systematically evaluated for safety. The compound's mechanism of proteasome inhibition suggests potential cytotoxicity, which may be desirable for anticancer applications but requires careful safety assessment. Standard toxicological endpoints including cell viability, genotoxicity, and organ toxicity should be evaluated. The compound is intended for research use only and is not approved for human use.
|
| References | |
| Additional Infomation |
There have been reports that tobacco contains 5-aminoquinoline-8-ol, and relevant data is available for reference.
5-Amino-8-hydroxyquinoline (5A8HQ) is a potential anticancer agent with notable proteasome inhibitory activity. The compound is a valuable research tool for studying protein degradation pathways, proteasome function, and cancer biology. As a bidentate heterocyclic compound, it also serves as a key intermediate in pharmaceutical synthesis. 5-Amino-8-hydroxyquinoline is intended for research use only and is not approved for therapeutic applications. |
| Molecular Formula |
C9H8N2O
|
|---|---|
| Molecular Weight |
160.17
|
| Exact Mass |
160.064
|
| CAS # |
13207-66-4
|
| PubChem CID |
416002
|
| Appearance |
Brown to black solid powder
|
| Density |
1.363g/cm3
|
| Boiling Point |
408.3ºC at 760 mmHg
|
| Vapour Pressure |
3E-07mmHg at 25°C
|
| Index of Refraction |
1.759
|
| LogP |
2.103
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
163
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC2=C(C=CC(=C2N=C1)O)N
|
| InChi Key |
YDEUKNRKEYICTH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H8N2O/c10-7-3-4-8(12)9-6(7)2-1-5-11-9/h1-5,12H,10H2
|
| Chemical Name |
5-aminoquinolin-8-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (624.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.2434 mL | 31.2168 mL | 62.4337 mL | |
| 5 mM | 1.2487 mL | 6.2434 mL | 12.4867 mL | |
| 10 mM | 0.6243 mL | 3.1217 mL | 6.2434 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
